Communiqués WuXi AppTec Co., Ltd. Hong Kong S.E.

Actions

2359

CNE100003F19

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:34 17/07/2024			Varia. 5j.	Varia. 1 janv.
29,3 ^HKD	+2,99 %		+6,16 %	-63,12 %

12/06	WuXi AppTec Co. approuve le versement d'un dividende en espèces pour l'exercice clos le 31 décembre 2023, payable le 5 juillet 2024	CI
06/06	Le personnel d'un fabricant de médicaments faisant l'objet d'une enquête américaine a travaillé avec des scientifiques de l'armée chinoise	RE

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Planning For The BIOSECURE Act	03/04	AQ
The BIOSECURE Act: Proposed New Legislation Could Affect U.S. Companies' Plans To Contract With Chinese Biotechnology Companies	21/03	AQ
Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security	24/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI for Advanced Melanoma	21/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma	21/02	AQ
WuXi AppTec : Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth	30/10/23	PU
WuXi AppTec : 2023 Third Quarterly Results Presentation	30/10/23	PU
Promega Corporation - DNA-Encoded Libraries and NanoBRET Target Engagement Assays Accelerate Drug Discovery	02/08/23	AQ
WuXi AppTec : 2023 Interim Results Presentation	31/07/23	PU
WuXi AppTec : First Quarter 2023 Results Presentation	24/04/23	PU
WuXi AppTec : 2022 Annual Results Presentation	23/03/23	PU
WuXi AppTec : Named “Industry Mover” in S&P Global Sustainability Yearbook 2023	16/02/23	PU
Delivering on the Promise of New Modalities: An Interview with Maria Luisa Pineda, CEO and Co-founder, Envisagenics	16/01/23	PU
WuXi AppTec : 2023 J.P. Morgan Presentation	11/01/23	PU
Delivering on the Promise of New Modalities: An Interview with SJ Lee, CEO, Orum Therapeutics	06/01/23	PU
WuXi STA and Multiply Labs announce partnership and successfully deploy robotic manufacturing system for personalized drugs	02/12/22	AQ
WuXi AppTec : 2022 Third Quarterly Results Presentation	26/10/22	PU
Delivering on the Promise of New Modalities: An Interview with Christopher Thanos, President, CEO & Co-Founder, Actym Therapeutics, Inc.	12/10/22	PU
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility	27/09/22	AQ
Delivering on the Promise of New Therapies for Rare Diseases: An Interview with Lili Mao, Director of Clinical Development Unit and Head of Project Management Office at GEXVal	20/09/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués WuXi AppTec Co., Ltd. Hong Kong S.E.

Actions

2359

CNE100003F19

Communiqués

Filtres